GlassScriptPhysician profile
Monica A Lee
NPI 1053888669
$3,867.26
in general payments reported to CMS, 2019-2025
26 companies · $3,189 in 2025
The $3,189 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $678 · 2025: $3,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994 · Travel and Lodging: $573 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.08 |
| Travel and Lodging | $573.20 |
| Education | $299.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $861.70 | 2025 | Interstim, Altaviva |
| Sumitomo Pharma America, INC. | $629.79 | 2024-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $345.93 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $270.42 | 2024-2025 | Provenge |
| Janssen Biotech, INC. | $224.48 | 2025 | Erleada |
| Astellas Pharma US INC | $214.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $185.13 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Calyxo, INC. | $145.62 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $141.54 | 2025 | |
| Tolmar, INC. | $106.91 | 2024-2025 | Jatenzo, Eligard |
| Vertex Pharmaceuticals Incorporated | $86.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.02 | 2024-2025 | Lynparza |
| Immunitybio, INC. | $76.20 | 2025 | |
| Telix Pharmaceuticals | $66.23 | 2025 | Illuccix |
| Urogen Pharma, INC. | $57.93 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $54.83 | 2024-2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $53.26 | 2024-2025 | Prolaris |
| Sun Pharmaceutical Industries INC. | $43.06 | 2025 | |
| Ferring Pharmaceuticals INC. | $38.58 | 2025 | Adstiladrin |
| Accord Healthcare, INC. | $33.87 | 2025 | |
| Coloplast Corp | $33.38 | 2025 | |
| Caris Mpi, INC. | $29.37 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $26.00 | 2025 | |
| Olympus America INC. | $24.10 | 2025 | Itind System |
| Abbvie INC. | $16.32 | 2025 | |
| Antares Pharma, INC. | $15.24 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.